Schumann, T. ; König, J.* ; von Loeffelholz, C.* ; Vatner, D.F.* ; Zhang, D.* ; Perry, R.J.* ; Bernier, M.* ; Chami, J.* ; Henke, C. ; Kurzbach, A. ; El-Agroudy, N.N. ; Willmes, D.M. ; Pesta, D.* ; de Cabo, R.* ; O Sullivan, J.F.* ; Simon, E.* ; Shulman, G.I.* ; Hamilton, B.S.* ; Birkenfeld, A.L.
Deletion of the diabetes candidate gene Slc16a13 in mice attenuates diet-induced ectopic lipid accumulation and insulin resistance.
Comm. Biol. 4:826 (2021)
Genome-wide association studies have identified SLC16A13 as a novel susceptibility gene for type 2 diabetes. The SLC16A13 gene encodes SLC16A13/MCT13, a member of the solute carrier 16 family of monocarboxylate transporters. Despite its potential importance to diabetes development, the physiological function of SLC16A13 is unknown. Here, we validate Slc16a13 as a lactate transporter expressed at the plasma membrane and report on the effect of Slc16a13 deletion in a mouse model. We show that Slc16a13 increases mitochondrial respiration in the liver, leading to reduced hepatic lipid accumulation and increased hepatic insulin sensitivity in high-fat diet fed Slc16a13 knockout mice. We propose a mechanism for improved hepatic insulin sensitivity in the context of Slc16a13 deficiency in which reduced intrahepatocellular lactate availability drives increased AMPK activation and increased mitochondrial respiration, while reducing hepatic lipid content. Slc16a13 deficiency thereby attenuates hepatic diacylglycerol-PKCε mediated insulin resistance in obese mice. Together, these data suggest that SLC16A13 is a potential target for the treatment of type 2 diabetes and non-alcoholic fatty liver disease.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Fatty Liver-disease; Induced Hepatic Steatosis; Monocarboxylate Transporter-1; Type-2; Variants; Lactate; Obesity; Association; Activation; Family
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2021
Prepublished im Jahr
HGF-Berichtsjahr
2021
ISSN (print) / ISBN
2399-3642
e-ISSN
2399-3642
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 4,
Heft: 1,
Seiten: ,
Artikelnummer: 826
Supplement: ,
Reihe
Verlag
Springer
Verlagsort
London
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
POF Topic(s)
90000 - German Center for Diabetes Research
Forschungsfeld(er)
Helmholtz Diabetes Center
PSP-Element(e)
G-502400-001
G-502600-012
Förderungen
Intramural Research Program of the National Institute on Aging, NIH
Boehringer Ingelheim Pharma GmbH Co. KG
Deutsche Diabetes Gesellschaft (German Diabetes Association)
Deutsche Diabetes Gesellschaft (DDG)
Deutsche Forschungsgemeinschaft (DFG, German Research foundation)
Copyright
Erfassungsdatum
2021-07-22